GW Pharmaceuticals, a biopharmaceutical company with a focus on cannabinoid-based medicines, has received fast track approval from the U.S. Food and Drug Administration (FDA) for a medicine designed to treat newborns deprived of oxygen during childbirth, which can lead to brain damage and death. The FDA gave approval to an intravenous form of cannabidiol (CBD) …
